Drug intelligence / Profile preview

Duradep

Development stage: Unknown
Lead developer: Ultramark Healthcare
Modality: Small Molecules
Administration: Oral

Overview

Duradep is a generic pharmaceutical formulation developed and manufactured by Ultramark Healthcare. It contains dapoxetine, a short-acting selective serotonin reuptake inhibitor (SSRI) specifically indicated for the treatment of premature ejaculation (PE) in adult men. The drug works by inhibiting the serotonin transporter (SERT), which increases serotonin levels in the synaptic cleft and subsequently delays the ejaculatory reflex. Unlike other SSRIs used for psychiatric conditions, dapoxetine is characterized by rapid absorption and a short half-life, making it suitable for on-demand administration prior to sexual activity.

Brand names: Duradep
Other names: dapoxetine

Targets

SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on Duradep.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Duradep.

Explore the full profile